The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas
T-cell engaging–therapies have transformed the treatment landscape of relapsed and refractory B-cell non-Hodgkin lymphomas by offering highly effective treatments for patients with historically limited therapeutic options. This review focuses on the advances in chimeric antigen receptor–modified T c...
Gespeichert in:
Veröffentlicht in: | Blood advances 2024-09, Vol.8 (17), p.4700-4710 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | T-cell engaging–therapies have transformed the treatment landscape of relapsed and refractory B-cell non-Hodgkin lymphomas by offering highly effective treatments for patients with historically limited therapeutic options. This review focuses on the advances in chimeric antigen receptor–modified T cells and bispecific antibodies, first providing an overview of each product type, followed by exploring the primary data for currently available products in large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. This review also highlights key logistical and sequencing considerations across diseases and product types that can affect clinical decision-making. |
---|---|
ISSN: | 2473-9529 2473-9537 2473-9537 |
DOI: | 10.1182/bloodadvances.2021004535 |